首页> 外文期刊>Nature Communications >Integrative discovery of treatments for high-risk neuroblastoma
【24h】

Integrative discovery of treatments for high-risk neuroblastoma

机译:综合发现高危神经母细胞瘤的治疗

获取原文
获取外文期刊封面目录资料

摘要

Despite advances in the molecular exploration of paediatric cancers, approximately 50% of children with high-risk neuroblastoma lack effective treatment. To identify therapeutic options for this group of high-risk patients, we combine predictive data mining with experimental evaluation in patient-derived xenograft cells. Our proposed algorithm, TargetTranslator, integrates data from tumour biobanks, pharmacological databases, and cellular networks to predict how targeted interventions affect mRNA signatures associated with high patient risk or disease processes. We find more than 80 targets to be associated with neuroblastoma risk and differentiation signatures. Selected targets are evaluated in cell lines derived from high-risk patients to demonstrate reversal of risk signatures and malignant phenotypes. Using neuroblastoma xenograft models, we establish CNR2 and MAPK8 as promising candidates for the treatment of high-risk neuroblastoma. We expect that our method, available as a public tool (targettranslator.org), will enhance and expedite the discovery of risk-associated targets for paediatric and adult cancers.
机译:尽管对儿科癌症的分子探索有所进展,但大约50%的高风险神经母细胞瘤的儿童缺乏有效的治疗方法。为了确定该组高风险患者的治疗选择,我们将预测数据挖掘与患者衍生的异种移植细胞的实验评估相结合。我们所提出的算法,靶标算法,从肿瘤生物汉,药理数据库和细胞网络中整合数据,以预测有针对性的干预如何影响与高患者风险或疾病过程相关的mRNA签名。我们发现超过80个目标与神经母细胞瘤风险和分化签名有关。在源自高风险患者的细胞系中评估所选靶标以证明风险签名和恶性表型的逆转。使用神经母细胞瘤异种移植模型,我们建立CNR2和MAPK8作为治疗高风险神经母细胞瘤的有希望的候选者。我们预计我们的方法可作为公共工具(TargetTransLator.org),将加强和加快对儿科和成人癌症的风险相关目标的发现。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号